


What is claimed is:

1. A compound of structural formula I:



(I), or a pharmaceutically acceptable salt thereof;

wherein:

“---” is a single bond or a double bond

X¹ is CH or N;

when “---” is a double bond, X² is CH or N;

when “---” is a single bond, X² is N(CH₃),

when X¹ is CH, X² is N or N(CH₃);

Y is -O-, -N(CH₃)-, -N(CH₂CH₂OH)-, cyclopropan-1,1-diyl, or -CH(CH₃)-

Q is 2-trifluoromethyl-4-fluorophenyl, 2-difluoromethyl-4-fluorophenyl, 2-trifluoromethylphenyl, 2-methyl-4-fluorophenyl, 2-chloro-4-fluorophenyl, 2-chlorophenyl, 1-(benzyl)-4-methylpiperidin-3-yl, 4-trifluoromethylpyridin-3-yl, 2-trifluoromethyl-6-fluorophenyl, 2-trifluoromethyl-3-cyanophenyl, 2-ethyl-3-fluorophenyl, 2-chloro-3-cyanophenyl, 2-trifluoromethyl-5-fluorophenyl, or 2-difluoromethylphenyl;


R³ is hydrogen, -CH₂OH, -CH(OH)-CH₂OH, -NH₂, -CH(OH)CH₃, -OCH₃, or -NH-(CH₂)₂OH; and when “---” is a double bond, R⁴ is absent;

and when “---” is a single bond, R³ and R⁴ are taken together to form =O; and

each of R⁵ and R⁶ is independently hydrogen or -CH₃,

provided that if X¹ is N, X² is N, Y is -O- or -N(CH₃)-, and Q is 2-trifluoromethylphenyl, then at least one of R³, R⁵, and R⁶ is not hydrogen.

2. The compound of claim 1, represented by structural formula II:









(II), or a pharmaceutically acceptable salt thereof; wherein:

R¹ is chloro, -CF₃, -CHF₂, or -CH₃;







R² is hydrogen or fluoro; and







R³ is hydrogen, -NH₂, -CH₂OH, or CH(OH)-CH₂OH.

3. The compound of claim 2, wherein when R¹ is -CHF₂, R² is not hydrogen.
4. The compound of claim 1, selected from any one of the following compounds, or a pharmaceutically acceptable salt thereof:

Compound	Structure
100	
101	
102	
103	
104	
105	

Compound	Structure
106	
107	
108	
109	
110	
111	

Compound	Structure
112	
113	
114	
115	
116	
117	

Compound	Structure
117a	
118	
119	
120	
121	
122	

Compound	Structure
123	
124	
125	
126	
126a	
127	

Compound	Structure
128	
129	
130	
131	
132	
133	

Compound	Structure
133a	
134	
135	
136	
137	
138	







Compound	Structure
139	
140	

5. The compound of claim 4, selected from any one of the following compounds, or a pharmaceutically acceptable salt thereof:

Compound	Structure	Compound	Structure
100		104	
101		105	
102		112	

Compound	Structure	Compound	Structure
113		128	
114		134	
116		135	
124		137	
125			

6. The compound of claim 5, selected from any one of the following compounds, or a pharmaceutically acceptable salt thereof:

Compound	Structure
100	
101	
102	
104	
105	
114	

Compound	Structure
116	
124	
125	
128	
134	
135	

Compound	Structure
137	

7. A pharmaceutical composition comprising a compound of any one of claims 1-6; and a pharmaceutically acceptable carrier.
8. A method of treating, or the reducing risk of developing, a disease or condition selected from kidney disease, pulmonary arterial hypertension, anxiety, depression, cancer, diabetic retinopathy, or pain, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-6, or a pharmaceutical composition of claim 7.
9. The method of claim 8, wherein the disease or condition is kidney disease selected from Focal Segmental Glomerulosclerosis (FSGS), Diabetic nephropathy, Alport syndrome, hypertensive kidney disease, nephrotic syndrome, steroid-resistant nephrotic syndrome, minimal change disease, membranous nephropathy, idiopathic membranous nephropathy, membranoproliferative glomerulonephritis (MPGN), immune complex-mediated MPGN, complement-mediated MPGN, Lupus nephritis, postinfectious glomerulonephritis, thin basement membrane disease, mesangial proliferative glomerulonephritis, amyloidosis (primary), c1q nephropathy, rapidly progressive GN, anti-GBM disease, C3 glomerulonephritis, hypertensive nephrosclerosis, or IgA nephropathy.
10. The method of claim 9, wherein the kidney disease is proteinuric kidney disease.

11. The method of claim 9, wherein the kidney disease is microalbuminuria or macroalbuminuria kidney disease.
12. The method of claim 8, wherein the disease or condition to be treated is pulmonary arterial hypertension.
13. The method of claim 8, wherein the disease or condition to be treated is pain selected from neuropathic pain, and visceral pain.
14. The method of claim 8, wherein the disease or condition is cancer selected from chemoresistant breast carcinoma, adriamycin-resistant breast cancer, chemoresistant colorectal cancer, medulloblastoma, and tumor angiogenesis.
15. The method of claim 8, wherein the disease or condition is transplant-related FSGS, transplant-related nephrotic syndrome, transplant-related proteinuria, cholestatic liver disease, polycystic kidney disease, autosomal dominant polycystic kidney disease (ADPKD), obesity, insulin resistance, Type II diabetes, prediabetes, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), or non-alcoholic steatohepatitis (NASH).
16. The method of any one of claims 8-15, wherein the subject is a human.